What changed for Cervical Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Cervical Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials on record 175 to 180 (+5)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Cervical Cancer yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Cervical Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03260023 · results posted 2 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03260023) enrolled a total of 143 participants across several groups. It tested a combination of two treatments — TG4001 (a type of vaccine-based therapy targeting HPV-16, a virus linked to certain cancers) and avelumab (an immunotherapy drug) — in people with advanced cancers that tested positive for HPV-16. The trial ran in phases: an early safety-focused phase (Phase I) with 9 participants, followed by larger Phase II stages involving the remaining participants, some of whom were randomly assigned to receive either the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01048853 · results posted 26 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 100 women diagnosed with early-stage cervical cancer (Stage IA2 or IB1) who had what were considered favourable features on pathology testing. Participants were placed into one of three groups depending on the type of surgery they received: a fertility-sparing approach (44 women), a cone biopsy followed by a simple hysterectomy and lymph node assessment (40 women), or a simple hysterectomy alone (16 women). The trial was measuring whether a more conservative (less extensive) surgical approach was practical and what th...
-
NCT03728881 · results posted 20 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03728881) enrolled 620 girls aged 9–14 and 620 women aged 18–25, giving a total of 1,240 participants. The girls received a single dose of one HPV vaccine (Cervarix®), while the women received three doses of a different HPV vaccine (Gardasil-4®). The trial was measuring how much of a specific immune response — called antibodies — each group produced against two strains of the human papillomavirus (HPV16 and HPV18) at 24 and 36 months after the first vaccination. Antibodies are proteins the body makes that can recognise a v...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03830866 · results posted 6 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03830866) enrolled 770 people in total — 385 in a group receiving durvalumab alongside standard chemoradiotherapy (a combination of chemotherapy and radiation), and 385 in a group receiving a placebo alongside the same standard chemoradiotherapy. The trial was measuring things like how long people went without their cancer growing or spreading (called progression-free survival), how long people lived overall, and how many people's tumours shrank or disappeared during treatment. The reported data shows that for the two mai...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01249365 · results posted 16 July 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 199 participants, all of whom received an HPV (human papillomavirus) vaccine. Of those, 198 completed the study and 1 did not. The trial was focused on tracking safety-related events — specifically, serious adverse events (unexpected or significant medical occurrences), medically significant conditions (medical issues serious enough to prompt an unplanned doctor or emergency room visit), and potential immune-related disorders, as well as any pregnancies that occurred during the study period. The reported data shows t...
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, public investment in cervical cancer research in the United States is described as a very large amount, which reflects that this condition has long been taken seriously as a global health priority. However, the direction of that funding is falling year on year, which may mean that some areas of research are maturing or that priorities are shifting. For patients, this...
See the full Cervical Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.